Genine Winslow, the CEO and Co-founder of Chameleon Biosciences, a biotechnology company focused on safer, more effective gene therapies joins eHealth Radio and the Health News Channel.
Chameleon’s (patent pending) EVADER™ platform is helping to make it possible to treat people who previously could not be treated with gene therapy, especially children with genetic diseases such as severe Hemophilia B.
Listen to host Eric Dye & guests Genine Winslow discuss the following:
Genine Winslow is the CEO and co-founder of Chameleon Biosciences, a biotechnology company she founded in 2017 focused on safer, more effective gene therapies. At Chameleon, Genine combines her backgrounds in both immunology and gene therapy to engineer a next generation AAV based vector for systemic repeat dosing for children and adults who today cannot be treated with conventional gene therapies. Prior to Chameleon, Winslow has led gene therapy scientific initiatives at multiple companies including Audentes Therapeutics, BioMarin, BlueBird Bio, and Cell Genesys.
Website: https://chameleonbiosci.com
Social Media Links:
Twitter: https://twitter.com/ChameleonBiosci
Linkedin: https://linkedin.com/company/chameleon-biosciences-inc
Create your
podcast in
minutes
It is Free
Copyright © 2006-2022 Podbean.com